Lupus sistémico y dermatomiositis infantil

Hochberg, 1997, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 40, 1725, 10.1002/art.1780400928 Ferraz, 1994, Evaluation of the 1982 ARA lupus criteria data set in pediatric patients, Clin Exp Rhumatol, 12, 83 Bader-Meunier, 2003, Childhood-onset systemic lupus erythematosus, Arch Pediatr, 10, 147, 10.1016/S0929-693X(03)00313-0 Lévy, 1989, Incidence du lupus érythémateux disséminé de l’enfant en région parisienne, Presse Med, 18, 2022 Bader-Meunier, 2005, Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study, J Pediatr, 146, 648, 10.1016/j.jpeds.2004.12.045 Wananukul, 1998, Cutaneous manifestations of childhood systemic lupus erythematosus, Pediatr Dermatol, 15, 342, 10.1046/j.1525-1470.1998.1998015342.x Mont, 1997, Risk factors for osteonecrosis in systemic lupus erythematosus, J Rheumatol, 24, 654 Niaudet, 2000, Treatment of lupus nephritis in children, Pediatr Nephrol, 14, 158, 10.1007/s004670050034 Gloor, 1998, Lupus nephritis in children, Lupus, 7, 639, 10.1191/096120398678920785 Sibbitt, 2002, The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus, J Rheumatol, 29, 1536 1999, Nomenclature and case definitions for neuropsychiatric lupus syndromes, Arthritis Rheum, 42, 599, 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F Bertsias, 2010, Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade, Ann Rheum Dis, 69, 1603, 10.1136/ard.2010.135186 Delgado, 1990, The pulmonary manifestations of childhood onset systemic lupus erythematosus, Semin Arthritis Rheum, 19, 285, 10.1016/0049-0172(90)90051-G Trapani, 1998, Pulmonary involvement in juvenile systemic lupus erythematosus: a study on lung function in patients asymptomatic for respiratory disease, Lupus, 7, 545, 10.1191/096120398678920631 Guevara, 2001, Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus, J Rheumatol, 28, 854 Urowitz, 2000, Accelerated atheroma in lupus-background, Lupus, 9, 161, 10.1191/096120300678828271 Sarkissian, 2007, Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus, Arthritis Rheum, 56, 631, 10.1002/art.22332 Gazarian, 1998, Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus, J Pediatr, 132, 109, 10.1016/S0022-3476(98)70494-9 Berube, 1998, The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study, Pediatr Res, 44, 351, 10.1203/00006450-199809000-00014 Montes de Oca, 1991, Thrombosis in systemic lupus erythematosus: a French collaborative study, Arch Dis Child, 66, 713, 10.1136/adc.66.6.713 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x Richer, 2007, Abdominal manifestations in childhood-onset systemic lupus erythematosus, Ann Rheum Dis, 66, 174, 10.1136/ard.2005.050070 Eberhard, 2001, Presence of thyroid abnormalities in children with systemic lupus erythematosus, J Pediatr, 119, 277, 10.1016/S0022-3476(05)80741-3 Malleson, 1997, Usefulness of antinuclear antibody testing to screen for rheumatic diseases, Arch Dis Child, 77, 299, 10.1136/adc.77.4.299 Silverman, 1997, Neonatal lupus erythematosus, Rheum Dis North Am, 2, 599, 10.1016/S0889-857X(05)70349-5 Shakoor, 2002, Drud-induced systemic lupus erythematosus associated with etanercept therapy, Lancet, 359, 579, 10.1016/S0140-6736(02)07714-0 Mitchell, 2002, C1q deficiency and autoimmunity: the effects of genetic background on disease expression, J Immunol, 68, 2538, 10.4049/jimmunol.168.5.2538 Rice, 2007, Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi-Goutières syndrome, Am J Hum Genet, 80, 811, 10.1086/513443 Costedoat-Chalumeau, 2008, Hydroxychloroquine and systemic lupus: a reappraisal, Rev Med Interne, 29, 735, 10.1016/j.revmed.2007.05.031 Wang, 1999, Discontinuation of antimalarial drugs in systemic lupus, J Rheumatol, 26, 808 Bader-Meunier, 2010, Childhood onset systemic lupus erythematosus: how does it must be treated in 2010?, Arch Pediatr, 17, 632, 10.1016/S0929-693X(10)70033-6 Sanz, 2010, Medscape B cells as therapeutic targets in SLE, Nat Rev Rheumatol, 6, 326, 10.1038/nrrheum.2010.68 Merrill, 2010, Rituximab: wanted dead or alive, Arthritis Rheum, 62, 2188, 10.1002/art.27544 Merrill, 2010, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial, Arthritis Rheum, 62, 222, 10.1002/art.27233 Houssiau, 2002, Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide, Arthritis Rheum, 46, 2121, 10.1002/art.10461 Kamanamool, 2010, Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis, Medicine, 89, 227, 10.1097/MD.0b013e3181e93d00 Houssiau, 2010, Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial, Ann Rheum Dis, 69, 2083, 10.1136/ard.2010.131995 Petri, 2005, Combined oral contraceptives in women with systemic lupus erythematosus, N Engl J Med, 352, 2550, 10.1056/NEJMoa051135 Compeyrot-Lacassagne, 2007, Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus, Arthritis Rheum, 56, 1966, 10.1002/art.22691 Bader-Meunier, 2004, Disseminated lupus erythematosus in children: guidelines about investigations during the initial evaluation and follow-up, Arch Pediatr, 11, 941, 10.1016/j.arcped.2004.01.027 Ravelli, 2005, Outcome in juvenile onset systemic lupus erythematosus, Curr Opin Rheumatol, 17, 568, 10.1097/01.bor.0000169364.69066.1e Ravelli, 2003, Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study, Arthritis Rheum, 49, 501, 10.1002/art.11205 Bohan, 1975, Polymyositis and dermatomyositis (first of two parts), N Engl J Med, 292, 344, 10.1056/NEJM197502132920706 Feldman, 2008, Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood, Lancet, 371, 2201, 10.1016/S0140-6736(08)60955-1 Wedderburn, 2007, International consensus on a proposed score system for muscle biopsy evaluation in patients with JDM, for potential use in clinical trials, Arthritis Rheum, 57, 1192, 10.1002/art.23012 Li, 2004, MHC class I overexpression on muscles in early juvenile dermatomyositis, J Rheumatol, 31, 605 Miles, 2007, Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients, Arthritis Rheum, 57, 1183, 10.1002/art.22993 Baechler, 2007, An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity, Mol Med, 13, 59, 10.2119/2006-00085.Baechler McCann, 2006, The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) clinical characteristics of children recruited within the first 5 years, Rheumatology, 45, 1255, 10.1093/rheumatology/kel099 Pachman, 1998, Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children, J Rheumatol, 25, 1198 Huber, 2004, Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies, Arthritis Rheum, 50, 1595, 10.1002/art.20179 Rider, 2010, Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies, Arthritis Care Res, 62, 465, 10.1002/acr.20035 Bode, 2003, Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence, Arthritis Rheum, 49, 7, 10.1002/art.10924 Ravelli, 2010, Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients, Arthritis Care Res, 62, 63, 10.1002/acr.20015 Pachman, 2000, TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications, Arthritis Rheum, 43, 2368, 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8 Mamyrova, 2007, Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy, Arthritis Rheum, 57, 881, 10.1002/art.22782 Russo, 2001, Cholestasis in juvenile dermatomyositis: report of three cases, Arthritis Rheum, 44, 1139, 10.1002/1529-0131(200105)44:5<1139::AID-ANR195>3.0.CO;2-M Gunawardena, 2009, Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression, Rheumatology, 48, 607, 10.1093/rheumatology/kep078 Gardner-Medwin, 2009, MRI in juvenile idiopathic arthritis and juvenile dermatomyositis, Ann N Y Acad Sci, 1154, 52, 10.1111/j.1749-6632.2009.04498.x Schmeling, 2011, Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis, Rheumatology, 50, 885, 10.1093/rheumatology/keq407 Stringer, 2008, Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features, Arthritis Rheum, 58, 3585, 10.1002/art.23960 Huber, 2000, Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis, Arthritis Rheum, 43, 541, 10.1002/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T Bingham, 2008, Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity, Medicine, 87, 70, 10.1097/MD.0b013e31816bc604 Huber, 2010, Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders, Arthritis Care Res, 62, 516, 10.1002/acr.20171 Sontheimer, 2010, Clinically amyopathic dermatomyositis: what can we now tell our patients?, Arch Dermatol, 146, 76, 10.1001/archdermatol.2009.323 Pediatric Rheumatology International Trials Organization. Juvenile dermatomyositis trial. www.printo.it/project_ongoing_detail.asp?ProjectID=14. Oddis C, Reed AM. Rituximab in myositis (RIM) study. www.edc.gsph.pitt.edu/rimstudy/. Ramanan, 2005, The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids, Arthritis Rheum, 52, 3570, 10.1002/art.21378 Heckmatt, 1989, Cyclosporin in juvenile dermatomyositis, Lancet, 1, 1063, 10.1016/S0140-6736(89)92456-2 Al-Mayouf, 2000, Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety, J Rheumatol, 27, 2498 Olson, 1989, Adjunctive use of hydroxychloroquine in childhood dermatomyositis, J Rheumatol, 16, 1545 Hollar, 2004, Topical tacrolimus in treatment for refractory skin disease in dermatomyositis: a pilot study, J Dermatolog Treat, 15, 35, 10.1080/09546630310018509 Riley, 2004, Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety, Rheumatology, 43, 491, 10.1093/rheumatology/keh082 Cooper, 2007, Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients, Arthritis Rheum, 56, 3107, 10.1002/art.22856 Rouster-Stevens, 2010, Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis, Arthritis Care Res, 62, 1446, 10.1002/acr.20269 Brewer, 1980, Plasma exchange therapy of a childhood onset dermatomyositis patient, Arthritis Rheum, 23, 509, 10.1002/art.1780230415 Ruperto, 2010, The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis, Arthritis Care Res, 62, 1533, 10.1002/acr.20280